[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 22 of about 22
1. Dufresne A, Gainet M, Stein U, Guardiola E, Pivot X: [Chemotherapy for patients with local-regional recurrent or metastatic carcinoma of the head and neck]. Bull Cancer; 2003 Jan;90(1):39-45
Hazardous Substances Data Bank. CETUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemotherapy for patients with local-regional recurrent or metastatic carcinoma of the head and neck].
  • [Transliterated title] Chimiothérapie des patients présentant une récidive locorégionale ou métastatique d'un cancer des voies aérodigestives supérieures.
  • Chemotherapy has emerged to be a central component of curative strategies for patient with primary squamous cell carcinoma of the head and neck.
  • A review of the relevant results obtained by the standard chemotherapy in this recurrent population is performed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Respiratory Tract Neoplasms / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Cetuximab. Gene Expression. Genes, p53 / physiology. Humans. Prognosis

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12609803.001).
  • [ISSN] 0007-4551
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; PQX0D8J21J / Cetuximab
  • [Number-of-references] 53
  •  go-up   go-down


2. Okuno SH, Mailliard JA, Suman VJ, Edmonson JH, Creagan ET, Nair S, Levitt R, Kugler JW: Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck. Cancer; 2002 Apr 15;94(8):2224-31
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck.
  • BACKGROUND: The chemotherapy drugs methotrexate, vinblastine, doxorubicin, and cisplatin have shown activity in patients with recurrent or metastatic squamous cell carcinoma arising from the upper respiratory or alimentary passages of the head and neck.
  • This study was undertaken to assess the antitumor activity and toxicity profile of the drug combination methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) in this patient population.
  • METHODS: Patients with histologically confirmed unresectable, recurrent, or metastatic squamous cell carcinoma arising from the upper respiratory or alimentary passages of the head and neck were treated with MVAC over a 4-week cycle.
  • Treatment was discontinued after four cycles for those whose disease remained stable.
  • Patients were evaluated for chemotherapy response, progression free survival, and survival.
  • Severe leukopenia (leukocyte count < 2000 cells/m3) was observed in 55% of the patients during the first cycle of treatment and in 81% of the patients during the entire course of their treatment.
  • The overall objective response rate over the first 4 cycles of treatment was 46% (90% confidence interval [CI], 33-60%).
  • The median time to progression was 19 weeks, and 1-year progression free survival rate was 17% (95% CI, 8-36%).
  • Among the 22 patients with unresected residual or recurrent disease, the median time to progression was 11 weeks, and 1-year progression free survival rate was 14% (95% CI, 5-39%), and median survival was 24 weeks, and the 1-year survival rate was 36% (95% CI, 21-63%).
  • Among the 13 patients with metastatic disease, the median time to progression was 26 weeks, and the 1-year progression free survival rate was 23% (95% CI, 9-62%), the median survival was 54 weeks, and the 1-year survival rate was 54% (95% CI, 33-89%).
  • CONCLUSIONS: Methotrexate, vinblastine, doxorubicin, and cisplatin is an active chemotherapy regimen in patients with recurrent or metastatic squamous cell cancer arising from the upper respiratory or alimentary passages of the head and neck.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Cisplatin / therapeutic use. Doxorubicin / therapeutic use. Head and Neck Neoplasms / drug therapy. Methotrexate / therapeutic use. Respiratory Tract Neoplasms / drug therapy. Vinblastine / therapeutic use
  • [MeSH-minor] Adult. Aged. Disease Progression. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neutropenia / chemically induced. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 American Cancer Society.
  • (PMID = 12001121.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-15083; United States / NCI NIH HHS / CA / CA-25224; United States / NCI NIH HHS / CA / CA-35103; United States / NCI NIH HHS / CA / CA-35113; United States / NCI NIH HHS / CA / CA-35195; United States / NCI NIH HHS / CA / CA-35269; United States / NCI NIH HHS / CA / CA-35415; United States / NCI NIH HHS / CA / CA-35448; United States / NCI NIH HHS / CA / CA-37404; United States / NCI NIH HHS / CA / CA-37417; United States / NCI NIH HHS / CA / CA-60276; United States / NCI NIH HHS / CA / CA-63849
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate; M-VAC protocol
  •  go-up   go-down


3. Lee HL, Ahn MJ, Choi JH, Jun WH, Lee YY, Kim IS, Choi IY, Jang SJ, Park YW: A case of NK/T-cell lymphoma complicated by a squamous cell carcinoma of hard palate during combination chemotherapy and radiation therapy. Korean J Intern Med; 2002 Mar;17(1):69-72
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of NK/T-cell lymphoma complicated by a squamous cell carcinoma of hard palate during combination chemotherapy and radiation therapy.
  • NK/T-cell lymphoma, which often shows an angiocentric growth pattern, is a distinct clinicopathologic entity highly associated with Epstein-Barr virus.
  • The disease is characterized by a destruction of the upper respiratory tract, particularly the nasal cavity, palate and paranasal sinuses.
  • Interestingly, NK/T-cell lymphoma is closely linked to a variety of complications, such as hemophagocytic syndrome, second primary cancer, sepsis and bleeding.
  • Here we report a case of a 50-year-old man diagnosed initially as NK/T-cell lymphoma of the oropharynx and who developed a second primary carcinoma of the hard palate during combination chemotherapy and radiation therapy.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Lymphoma, T-Cell / pathology. Neoplasms, Second Primary / pathology. Oropharyngeal Neoplasms / pathology. Palatal Neoplasms / pathology
  • [MeSH-minor] Combined Modality Therapy. Fatal Outcome. Humans. Killer Cells, Natural. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12014217.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC4531653
  •  go-up   go-down


Advertisement
4. Urabe N, Kageyama Y, Watanabe K: [Bronchopleural fistula after pneumonectomy following induction therapy for cT4N0M0 squamous cell lung cancer]. Kyobu Geka; 2000 May;53(5):417-9
MedlinePlus Health Information. consumer health - Pleural Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bronchopleural fistula after pneumonectomy following induction therapy for cT4N0M0 squamous cell lung cancer].
  • A 69-year-old man developed after thoracotomy for lung cancer.
  • He had centrally located cT4N0M0 squamous cell lung cancer that was downstaged to cTxN0M0 by induction chemoradiotherapy with grade 3 hematologic toxicity.
  • Two months after the finish of chemotherapy, right pneumonectomy with concomitant resection of the superior vena cava was performed.
  • Three weeks later, he developed with a bronchopleural fistula and died of ARDS.
  • [MeSH-major] Bronchial Fistula / etiology. Carcinoma, Squamous Cell / therapy. Lung Neoplasms / therapy. Pleural Diseases / etiology. Pneumonectomy. Postoperative Complications. Respiratory Tract Fistula / etiology
  • [MeSH-minor] Aged. Combined Modality Therapy. Humans. Male. Remission Induction

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10808294.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] JAPAN
  •  go-up   go-down


6. Matsusaka K, Kinoshita Y, Udagawa H, Fukayama M, Ohashi K: Squamous cell carcinoma arising in a communicating bronchopulmonary-foregut malformation. Hum Pathol; 2010 Nov;41(11):1650-4
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma arising in a communicating bronchopulmonary-foregut malformation.
  • Communicating bronchopulmonary-foregut malformation, a variant of bronchopulmonary sequestration, is a rare anomaly characterized by communication between an isolated portion of the respiratory tree and the gastrointestinal tract.
  • We report herein a unique case involving a 43-year-old man with squamous cell carcinoma arising in communicating bronchopulmonary-foregut malformation.
  • This patient had a workup for a chief complaint of exacerbation of constitutional dysphagia, resulting in detection of squamous cell carcinoma involving the lower esophagus.
  • Under the clinical diagnosis of esophageal carcinoma, esophagectomy was performed after neoadjuvant chemoradiotherapy.
  • Pathologic findings showed that squamous cell carcinoma had arisen in malformed bronchopulmonary tissue constituting part of the distal esophagus segmentally.
  • This case was unique in that squamous cell carcinoma developed in an extremely rare type of congenital abnormality that had functioned as a passageway for food from birth, as a result of chronic irritation for more than 4 decades.
  • [MeSH-major] Bronchopulmonary Sequestration / pathology. Carcinoma, Squamous Cell / pathology. Esophageal Neoplasms / pathology. Esophagus / abnormalities
  • [MeSH-minor] Adult. Drug Therapy, Combination. Esophagectomy. Humans. Male. Neoadjuvant Therapy. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20537686.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Yano M, Shiozaki H, Tsujinaka T, Inoue M, Doki Y, Fujiwara Y, Monden M: Squamous cell carcinoma of the esophagus infiltrating the respiratory tract is less sensitive to preoperative concurrent radiation and chemotherapy. J Am Coll Surg; 2000 Dec;191(6):626-34
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the esophagus infiltrating the respiratory tract is less sensitive to preoperative concurrent radiation and chemotherapy.
  • BACKGROUND: The prognosis of upper thoracic esophageal cancer is poor when compared with middle and lower thoracic esophageal cancer because the tumor easily infiltrates the respiratory tract and surgical en-bloc resection is difficult.
  • Recently, preoperative chemoradiation therapy has been shown to lead to down-staging of the disease and improve prognosis.
  • But the benefit of this therapy for tumors infiltrating the respiratory tract remains unknown.
  • STUDY DESIGN: Fifty-six patients with thoracic esophageal cancer infiltrating neighboring organs, but with no hematogeneous metastasis, were given preoperative concurrent chemotherapy (5-fluorouracil and cisplatin) and radiation (40 Gy) therapy.
  • RESULTS: The prognosis was significantly poorer for patients with tumors infiltrating the respiratory tract (T) or aorta plus respiratory tract (A + T) than for patients with tumors infiltrating the aorta alone (A) or other organs (Oth) (p < 0.05 for Oth versus T; p < 0.05 for Oth versus A + T; p < 0.0001 for A versus T; p < 0.0001 for A versus A + T by log-rank test).
  • Patients positive for respiratory tract invasion (T, T + A), compared with those negative for respiratory tract invasion (A, Oth), showed a poorer clinical response to chemoradiation (3.0%, 45.5%, 39.4%, and 9.1% versus 4.3%, 82.6%, 4.3%, and 8.7% in complete response (CR), partial response (PR), nonresponse (NC) and progressive disease (PD), respectively, p = 0.0156) and surgical resectability (36.4% vs. 87.0%, p = 0.0003).
  • Histologic effectiveness (8.3%, 50.0%, and 41.7% versus 25.0%, 70.0%, and 5.0% in grade 3, grade 2, and grade 1, respectively, for patients with respiratory tract invasion versus those without it, p = 0.0189) and histologic stages (8.3%, 8.3%, 8.3%, 8.3%, 25.0%, and 41.7% versus 20.0%, 0%, 15.0%, 25.0%, 40.0%, and 0% in pathologic CR, stage I, stage IIA, stage IIB, stage III, and stage IV, respectively, for patients with respiratory tract invasion versus those without it, p = 0.0496) were significantly better in patients negative for respiratory tract invasion; the percentages of patients with lymph node metastasis did not differ significantly between the two groups.
  • Comparison of the recurrence patterns showed that local failure was most common in patients with respiratory tract invasion, and distant failure was the leading cause of recurrence in patients without it.
  • CONCLUSIONS: Because the prognosis of patients with thoracic esophageal cancer infiltrating the respiratory tract is extremely poor, partially because of the low local effectiveness of preoperative concurrent chemotherapy and radiation therapy, caution is needed when deciding on salvage surgery.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / therapy. Drug Tolerance. Esophageal Neoplasms / pathology. Esophagectomy. Preoperative Care / methods. Radiation Tolerance. Respiratory Tract Neoplasms / secondary. Respiratory Tract Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Lymph Node Excision. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Prognosis. Proportional Hazards Models. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11129811.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


8. Prasad ML, Busam KJ, Patel SG, Hoshaw-Woodard S, Shah JP, Huvos AG: Clinicopathologic differences in malignant melanoma arising in oral squamous and sinonasal respiratory mucosa of the upper aerodigestive tract. Arch Pathol Lab Med; 2003 Aug;127(8):997-1002
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic differences in malignant melanoma arising in oral squamous and sinonasal respiratory mucosa of the upper aerodigestive tract.
  • We compare melanomas arising in 2 histologically different mucosa, the stratified oral squamous mucosa and pseudostratified sinonasal respiratory mucosa, to investigate the clinicopathologic influence of native mucosal histology on the tumor.
  • METHODS: Clinicopathologic features of 36 melanomas arising in the squamous mucosa of the oral cavity were compared with 59 melanomas arising in the sinonasal respiratory mucosa.
  • RESULTS: The median age of patients was 61 and 63 years for oral and sinonasal melanomas, respectively, with the squamous and respiratory mucosa covering the maxilla being most frequently involved (68.7% and 66%, respectively).
  • Sinonasal melanoma showed vascular and deep tissue invasion more frequently than oral melanoma; however, no significant difference in disease-specific survival was noted (median survival, 2.8 years vs 3.0 years; 5-year survival, 37% vs 35%, respectively).
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Head and Neck Neoplasms / pathology. Maxillary Sinus Neoplasms / pathology. Melanoma / pathology. Mouth Mucosa / pathology. Mouth Neoplasms / pathology. Nose Neoplasms / pathology. Respiratory Mucosa / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Nasal Mucosa / drug effects. Nasal Mucosa / pathology. Nasal Mucosa / surgery. Neoplasm Invasiveness / pathology. Paranasal Sinus Neoplasms / drug therapy. Paranasal Sinus Neoplasms / mortality. Paranasal Sinus Neoplasms / pathology. Paranasal Sinus Neoplasms / surgery


9. Lin HW, Richmon JD, Emerick KS, de Venecia RK, Zeitels SM, Faquin WC, Lin DT: Malignant transformation of a highly aggressive human papillomavirus type 11-associated recurrent respiratory papillomatosis. Am J Otolaryngol; 2010 Jul-Aug;31(4):291-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of a highly aggressive human papillomavirus type 11-associated recurrent respiratory papillomatosis.
  • OBJECTIVE: The objective is to present an uncommon case of squamous cell carcinoma (SCC) arising from extensive recurrent respiratory papillomatosis (RRP) involving the upper and lower airway and temporal bone.
  • METHODS: We describe a case of a 24-year-old woman with a history of human papillomavirus (HPV) type 11 since childhood originating in the larynx and trachea, then progressing to involve the distal pulmonary alveoli and right middle ear through the eustachian tube.
  • Papillomatous growth was treated with multiple surgeries including laser cytoreduction of laryngotracheal papillomatosis and radical mastoidectomy, followed by a trial of chemotherapy.
  • Despite this aggressive treatment regimen, papillomatous growth progressed with recurrence in the right eustachian tube, middle ear, and mastoid eventually extending to involve the calvaria and scalp.
  • RESULTS: The patient underwent a composite resection of involved tissues, including the scalp, auricle, and lateral temporal bone, with reconstruction using a latissimus dorsi free flap.
  • A review of the literature on aggressive respiratory papillomatosis suggests that malignant transformation of juvenile-onset RRP occurs exclusively in cases positive for HPV-11.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Human papillomavirus 11. Papilloma / pathology. Respiratory Tract Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Disease Progression. Female. Humans. Neoplasm Recurrence, Local. Tomography, X-Ray Computed. Young Adult

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20015762.001).
  • [ISSN] 1532-818X
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Wakisaka N, Murono S, Kondo S, Furukawa M, Yoshizaki T: Post-operative pharyngocutaneous fistula after laryngectomy. Auris Nasus Larynx; 2008 Jun;35(2):203-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we evaluated the cause of PCF after laryngectomy, with special emphasis on radiotherapy and/or chemotherapy.
  • PATIENTS AND METHODS: A total of 63 consecutive patients undergoing salvage total laryngectomy for squamous cell carcinoma of the larynx at Kanazawa University Hospital from 1990 to 2005 were reviewed.
  • RESULTS: Overall, 17 of the 63 patients (27.0%) developed PCF after laryngectomy.
  • CONCLUSIONS: Although radiotherapy or chemotherapy has only a limited impact on PCF formation, concurrent chemoradiotherapy significantly increases PCF formation.
  • The addition of chemotherapy to irradiation delays PCF closure.
  • [MeSH-major] Cutaneous Fistula / etiology. Laryngectomy. Pharyngeal Diseases / etiology. Respiratory Tract Fistula / etiology
  • [MeSH-minor] Carcinoma, Squamous Cell / therapy. Chemotherapy, Adjuvant / adverse effects. Female. Humans. Laryngeal Neoplasms / therapy. Male. Middle Aged. Postoperative Complications. Radiotherapy, Adjuvant / adverse effects. Salvage Therapy

  • MedlinePlus Health Information. consumer health - Throat Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17826021.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


11. Chaigneau L, Villanueva C, Thierry-Vuillemin A, Legat-Fagnoni C, N'Guyen T, Maurina T, Lorgis V, Pivot X: [Pemetrexed development in oncology]. Bull Cancer; 2007;94 Spec No Actualites:S142-8
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The pemetrexed disodium (Alimta), LY231514) is the first antifolate able to inhibit at the same time the synthesis of purins and pyrimidins.
  • Many therapeutic tests were carried out in clinical situations where the methotrexate and the fluorouracil had been the proof of their effectiveness.
  • The two randomized studies carried out in the malignant pleural mesothelioma and the non small cell lung cancer made it possible to establish its utility and to record the pemetrexed in these clinical situations.
  • Others axes of development remain possible, but the results are stanby or to confirm as in squamous-cell cancer in the head and neck and breast, digestive or urinary tracts cancer.
  • In all the cases, the optimization of the pemetrexed in terms of amount/methods of administration and associations possible because of its profile of tolerance makes of it a molecule of chemotherapy with a future.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Glutamates / therapeutic use. Guanine / analogs & derivatives
  • [MeSH-minor] Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Small Cell / drug therapy. Digestive System Neoplasms / drug therapy. Enzyme Inhibitors / therapeutic use. Female. Humans. Lung Neoplasms / drug therapy. Male. Mesothelioma / drug therapy. Pemetrexed. Pleural Neoplasms / drug therapy. Respiratory Tract Neoplasms / drug therapy. Urogenital Neoplasms / drug therapy

  • Hazardous Substances Data Bank. PEMETREXED .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17845985.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Enzyme Inhibitors; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine
  • [Number-of-references] 58
  •  go-up   go-down


12. Hanazono K, Natsugoe S, Okumura H, Matsumoto M, Oowaki T, Setoyama T, Hiraki Y, Arimura K, Nakamura F, Nakajo M, Aikou T: [An effective treatment by chemoradiation therapy after stent insertion for advanced esophageal cancer with esophago-pulmonary fistula--report of a case]. Gan To Kagaku Ryoho; 2007 Aug;34(8):1275-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An effective treatment by chemoradiation therapy after stent insertion for advanced esophageal cancer with esophago-pulmonary fistula--report of a case].
  • He received radiation therapy in combination with chemotherapy using cisplatin and 5-FU after insertion of a self-expanding metallic stent.
  • The CRT after insertion of self-expanding metallic stent is one of the useful and palliative treatments for advance esophageal cancer with esophago-pulmonary fistula.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Esophageal Fistula / complications. Esophageal Neoplasms / therapy. Lung Abscess / complications. Lung Diseases / complications. Lymph Nodes / pathology. Respiratory Tract Fistula / complications. Stents
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Esophageal Stenosis / therapy. Fluorouracil / administration & dosage. Humans. Lymphatic Metastasis. Male. Middle Aged. Remission Induction

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17687212.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; CF regimen
  •  go-up   go-down


13. Hitzman CJ, Wattenberg LW, Wiedmann TS: Pharmacokinetics of 5-fluorouracil in the hamster following inhalation delivery of lipid-coated nanoparticles. J Pharm Sci; 2006 Jun;95(6):1196-211
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The inhalation delivery of 5-fluorouracil (5-FU) in lipid-coated nanoparticles (LNPs) to hamsters was evaluated to determine the feasibility for use in lung cancer chemotherapy.
  • The concentration of FITC-dextran and total 5-FU (released and LNP-associated) was determined as a function of time in the lung, trachea, larynx, esophagus, and serum.
  • Within 24 h, greater than 99% of the LNPs were cleared from the respiratory tract and total 5-FU concentrations mirrored the LNP concentration.
  • An eight-compartment pharmacokinetic model was used to describe the observed trends in concentrations of LNPs and total 5-FU and to estimate the released 5-FU concentration in the above tissues.
  • [MeSH-minor] Administration, Inhalation. Aerosols. Animals. Carcinoma, Squamous Cell / drug therapy. Cricetinae. Delayed-Action Preparations. Dextrans / chemistry. Feasibility Studies. Fluorescein-5-isothiocyanate. Fluorescent Dyes. Lipids / chemistry. Lung Neoplasms / drug therapy. Male. Mesocricetus. Particle Size. Tissue Distribution

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc. and the American Pharmacists Association
  • (PMID = 16639722.001).
  • [ISSN] 0022-3549
  • [Journal-full-title] Journal of pharmaceutical sciences
  • [ISO-abbreviation] J Pharm Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aerosols; 0 / Antimetabolites, Antineoplastic; 0 / Delayed-Action Preparations; 0 / Fluorescent Dyes; 0 / Lipids; I223NX31W9 / Fluorescein-5-isothiocyanate; K3R6ZDH4DU / Dextrans; U3P01618RT / Fluorouracil
  •  go-up   go-down


14. Davids PH, Bartelsman JF, Tilanus HW, van Lanschot JJ: [Consequences of caustic damage of the esophagus]. Ned Tijdschr Geneeskd; 2001 Nov 3;145(44):2105-8
Hazardous Substances Data Bank. ACETIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Following ingestion of a highly concentrated acetic acid solution, three women aged 29, 23 and 25 years old, suffered damage to the oesophagus and the stomach, respiratory and renal insufficiency and haemolysis.
  • After intensive treatment, gastric tube reconstruction was carried out in 2 of these patients, and the third woman required repeated dilatations of the oesophageal stricture from 6 weeks after ingestion onwards.
  • A squamous cell carcinoma was diagnosed and treated with chemotherapy, oesophagus-cardia resection and gastric tube reconstruction.
  • Ingestion of corrosive substances can lead to serious damage of the gastrointestinal tract.
  • Subsequent treatment can vary from endoscopic dilations to gastric tube reconstruction following resection of the oesophagus.
  • [MeSH-minor] Acetic Acid / adverse effects. Adult. Carcinoma, Squamous Cell / etiology. Carcinoma, Squamous Cell / surgery. Deglutition Disorders / etiology. Dilatation / methods. Esophageal Neoplasms / etiology. Esophageal Neoplasms / surgery. Esophagus / pathology. Esophagus / surgery. Female. Humans. Male. Middle Aged. Secondary Prevention. Sodium Hydroxide / adverse effects. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophagus Disorders.
  • Hazardous Substances Data Bank. SODIUM HYDROXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11723750.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 55X04QC32I / Sodium Hydroxide; Q40Q9N063P / Acetic Acid
  • [Number-of-references] 9
  •  go-up   go-down


15. Wutzl A, Ploder O, Kermer C, Millesi W, Ewers R, Klug C: Mortality and causes of death after multimodality treatment for advanced oral and oropharyngeal cancer. J Oral Maxillofac Surg; 2007 Feb;65(2):255-60
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mortality and causes of death after multimodality treatment for advanced oral and oropharyngeal cancer.
  • PATIENTS AND METHODS: A total of 222 patients who underwent multimodality treatment from 1990 to 2000 were included in the study.
  • Patients received preoperative radiotherapy 50 Gy and concomitant chemotherapy with mitomycin and 5-fluorouracil.
  • Of these, a second cancer in the head and neck region or the lower respiratory tract or the upper digestive tract was found in 7.3%.
  • CONCLUSION: Favorable survival data were registered for patients with advanced squamous cell carcinoma of the oral cavity who underwent combined treatment protocols.
  • [MeSH-major] Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / therapy. Mouth Neoplasms / mortality. Mouth Neoplasms / therapy
  • [MeSH-minor] Cause of Death. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / mortality. Neoplasms, Second Primary / mortality. Oropharyngeal Neoplasms / mortality. Oropharyngeal Neoplasms / surgery. Oropharyngeal Neoplasms / therapy. Radiotherapy, Adjuvant. Retrospective Studies. Time Factors

  • Genetic Alliance. consumer health - Oral cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17236930.001).
  • [ISSN] 0278-2391
  • [Journal-full-title] Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • [ISO-abbreviation] J. Oral Maxillofac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


16. Ouedraogo M, Zigani A, Ouedraogo SM, Zoubga AZ, Birba E, Badoum G, Bambara M, Ki C, Ouedraogo G, Drabo YJ: [Contribution of bronchial fibroscopy in pneumonology services in developing countries]. Rev Mal Respir; 2001 Jun;18(3):297-300

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bronchial fibroscopy is a recent investigation method that requires equipment and facilities difficult to implement in respiratory diseases units in developing countries.
  • In Burkina Faso, this technique was introduced for the first time in February 1997.
  • The purpose of this study was to determine the contribution of bronchial fibroscopy for the diagnosis of respiratory disease in countries with limited resources.
  • This study was conducted between February 1997 and October 1998 at the respiratory diseases unit of the Yalgado Ouedraogo National Hospital Center in Ouagadougou, Burkina Faso.
  • Ten cases of lung cancer were diagnosed (40% squamous cell carcinoma).
  • Malignant disease is a reality in developing countries despite low rates of diagnosis due to insufficient diagnostic facilities.
  • For tuberculosis, the importance of specific treatment is certainly well established and should always be initiated, even if fibroscopy cannot be performed.
  • This contrasts with the situation for malignant disease, where the high prevalence of lung cancer (9.9% of the bronchial fibroscopies performed) is associated with total lack of treatment due to the absence of a thoracic surgery unit or a radiotherapy unit, and the impossibility of providing satisfactory surveillance of anti-cancer chemotherapy.
  • [MeSH-major] Bronchoscopy / economics. Developing Countries. Respiratory Tract Diseases / diagnosis
  • [MeSH-minor] Burkina Faso. Health Services / economics. Humans. Lung Diseases / diagnosis. Lung Diseases / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Rev Mal Respir. 2001 Jun;18(3):237-8 [11468583.001]
  • (PMID = 11468591.001).
  • [ISSN] 0761-8425
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


17. Baumeister P, Schwenk-Zieger S, Reiter M, Welz C, Harréus U: Transforming Growth Factor-alpha reduces carcinogen-induced DNA damage in mini-organ cultures from head-and-neck cancer patients. Mutat Res; 2009 Jun-Jul;677(1-2):42-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EGFR is over-expressed in up to 90-100% of head-and-neck squamous cell carcinomas (HNSCC), and increased expression of EGFR and its ligand Transforming Growth Factor-alpha (TGF-alpha) is not limited to malignant cells, but also detected in histologically normal mucosa of HNSCC patients, supporting the hypothesis of field carcinogenesis.
  • Permanent EGFR activation via an autocrine stimulatory pathway is thought to be a major factor forcing pre-neoplastic tissue towards malignancy.
  • Our study evaluates the impact of stimulation by TGF-alpha on carcinogen-induced and oxidative DNA damage in mucosa tissue cultures of macroscopically normal biopsies from tumour patients and controls.
  • To assess DNA fragmentation, alkaline single-cell gel electrophoresis (comet assay) was used.
  • It was shown in clinical studies, that EGFR targeting has synergistic effects with chemotherapy in HNSCC and reverses chemo-resistance of epithelial tumours, which was shown to be the consequence of altered expression of multidrug resistance (mdr) efflux pumps.
  • However, our results show a strong DNA-stabilizing effect of stimulation by TGF-alpha in mucosa tissue cultures of tumour patients and may therefore be seen as a physiological response to continued carcinogenic impact on the epithelium of the upper aerodigestive tract.
  • [MeSH-major] Carcinoma, Squamous Cell / genetics. DNA Damage / drug effects. Head and Neck Neoplasms / genetics. Transforming Growth Factor alpha / pharmacology
  • [MeSH-minor] 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide / toxicity. Carcinogens. DNA Fragmentation / drug effects. DNA Repair. Humans. Hydrogen Peroxide / pharmacology. Mouth Mucosa / ultrastructure. Organ Culture Techniques. Respiratory Mucosa / ultrastructure

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19539778.001).
  • [ISSN] 0027-5107
  • [Journal-full-title] Mutation research
  • [ISO-abbreviation] Mutat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Transforming Growth Factor alpha; 55097-80-8 / 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide; BBX060AN9V / Hydrogen Peroxide
  •  go-up   go-down


18. Avendano CE, Flume PA, Silvestri GA, King LB, Reed CE: Pulmonary complications after esophagectomy. Ann Thorac Surg; 2002 Mar;73(3):922-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, the role that preoperative treatment with chemotherapy and radiation may play in postoperative complications remains unclear.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / surgery. Esophagectomy / adverse effects. Respiratory Tract Diseases / etiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Thorac Surg. 2004 Apr;77(4):1503 [15063305.001]
  • [CommentIn] Ann Thorac Surg. 2002 Nov;74(5):1747 [12440654.001]
  • [CommentIn] Ann Thorac Surg. 2003 Feb;75(2):634-5 [12607699.001]
  • (PMID = 11899202.001).
  • [ISSN] 0003-4975
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Sonobe M, Nakagawa M, Ichinose M, Ikegami N, Nagasawa M, Shindo T: Analysis of risk factors in bronchopleural fistula after pulmonary resection for primary lung cancer. Eur J Cardiothorac Surg; 2000 Nov;18(5):519-23
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: BPFs developed in ten patients (1.8%).
  • Previous ipsilateral thoracotomy (P<0.01; odds ratio, 37.9) and preoperative chemotherapy and/or radiotherapy (P=0.02; odds ratio, 13.2) increased the risk.
  • The incidence of BPFs with manual suture, stapling devices only, reinforcement suture at the distal side of staplers, or reinforcement suture at the proximal side of staplers was 1.8, 5.0, 1.9 and 1.0%, respectively.
  • CONCLUSIONS: The main and intermediate bronchial stumps, and the stumps in cases with previous ipsilateral thoracotomy or receiving induction therapy are prone to BPFs.
  • [MeSH-major] Adenocarcinoma / surgery. Bronchial Fistula / etiology. Carcinoma, Squamous Cell / surgery. Lung Neoplasms / surgery. Pleural Diseases / etiology. Pneumonectomy / adverse effects. Respiratory Tract Fistula / etiology. Surgical Stapling / methods. Suture Techniques
  • [MeSH-minor] Aged. Aged, 80 and over. Chi-Square Distribution. Combined Modality Therapy. Female. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Odds Ratio. Retrospective Studies. Risk Factors. Treatment Outcome. Wound Healing

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pleural Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11053810.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ENGLAND
  •  go-up   go-down


20. Jain S, Agarwal J, Laskar S, Gupta T, Shrivastava S: Radiation recall dermatitis with gatifloxacin: a review of literature. J Med Imaging Radiat Oncol; 2008 Apr;52(2):191-3
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Radiation recall dermatitis (RRD) is a hypersensitivity skin reaction at the previously irradiated site after the administration of certain pharmacologic agent, which recovers on stopping the medication.
  • We report here a case of RRD with the use of gatifloxacin and describe the time dose factors of radiation exposure, characteristics of skin reactions, management and response and our reasons to label this case as RRD.
  • We also discuss published work regarding proposed mechanisms, histological features, radiation dose threshold and response to rechallange with the RRD-triggering drug.
  • If RRD is to be characterized unequivocally, all the potential areas of confusion must be clarified like radiosensitization, nonhealing of acute reactions and skin-related adverse effects of the RRD-triggering drug.
  • [MeSH-major] Anti-Infective Agents / adverse effects. Carcinoma, Squamous Cell / radiotherapy. Fluoroquinolones / adverse effects. Mouth Neoplasms / radiotherapy. Radiodermatitis / chemically induced
  • [MeSH-minor] Dose-Response Relationship, Radiation. Drug Eruptions / etiology. Female. Follow-Up Studies. Humans. Middle Aged. Radiation-Sensitizing Agents / administration & dosage. Radiation-Sensitizing Agents / adverse effects. Respiratory Tract Infections / drug therapy. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18373813.001).
  • [ISSN] 1754-9485
  • [Journal-full-title] Journal of medical imaging and radiation oncology
  • [ISO-abbreviation] J Med Imaging Radiat Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 0 / Fluoroquinolones; 0 / Radiation-Sensitizing Agents; L4618BD7KJ / gatifloxacin
  •  go-up   go-down


21. Rollins M, McKay WR, McKay RE: Airway difficulty after a brachial plexus subclavian perivascular block. Anesth Analg; 2003 Apr;96(4):1191-2, table of contents
Hazardous Substances Data Bank. EPINEPHRINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Brachial Plexus. Nerve Block / adverse effects. Respiratory Tract Diseases / chemically induced. Vocal Cord Paralysis / chemically induced
  • [MeSH-minor] Aged. Anesthetics, Local / adverse effects. Bupivacaine / adverse effects. Carcinoma, Squamous Cell / surgery. Epinephrine / adverse effects. Female. Humans. Oxygen Inhalation Therapy. Respiratory Sounds / drug effects. Tongue Neoplasms / surgery. Vasoconstrictor Agents / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12651683.001).
  • [ISSN] 0003-2999
  • [Journal-full-title] Anesthesia and analgesia
  • [ISO-abbreviation] Anesth. Analg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anesthetics, Local; 0 / Vasoconstrictor Agents; Y8335394RO / Bupivacaine; YKH834O4BH / Epinephrine
  •  go-up   go-down


22. Ramnath N, Khushalani N, Toth K, Litwin AM, Intengan ME, Slocum HK, Pendyala L, Smith PF, Stewart CC, Hoffman JL, Javle MM, Berdzik J, Creaven PJ, Rustum YM: S-phase modulation by irinotecan: pilot studies in advanced solid tumors. Cancer Chemother Pharmacol; 2005 Nov;56(5):447-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Doses of 20-80 mg/m(2) were explored to establish the MTD and DLT and to study tumor cell S-phase in selected patients.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Gastrointestinal Neoplasms / drug therapy. Respiratory Tract Neoplasms / drug therapy. S Phase / drug effects
  • [MeSH-minor] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / pharmacokinetics. Biopsy. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Squamous Cell / drug therapy. Cyclin A / analysis. Cyclin A / metabolism. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Deoxycytidine / pharmacokinetics. Female. Fluorouracil / administration & dosage. Fluorouracil / pharmacokinetics. Humans. Male. Maximum Tolerated Dose

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15947933.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 55070806; United States / NCI NIH HHS / CA / CA16056
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / Cyclin A; 0W860991D6 / Deoxycytidine; 7673326042 / irinotecan; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down






Advertisement